比利时Delphi Genetics S.A.  
Delphi Genetics SA 创办于2001年末，采用其在质粒稳定系统领域的独家专长开发用于基因工程和细菌中蛋白质表达的更高效的产品和技术。Delphi已获专利的Staby®技术能够增加重组蛋白的产量，而不需要像传统方法那样使用抗生素。此外，该技术满足FDA (美国食品和药物管理局)和EMA (欧洲药品局)就在人和兽用蛋白质生产工艺中消除耐抗生素基因的各项建议。该公司已经宣布了与赛诺菲-巴斯德公司和葛兰素史克公司（GSK）等一些重要制药集团达成的几项许可协议。

Founded in 2001, Delphi Genetics S.A., located in Gosselies Belgium, focuses on developing new, much more effective products and technologies for gene cloning and protein expression in bacteria.

The products and services developed by Delphi Genetics are based on unique technologies using bacterial poison-antidote genes. Our patented Staby® technology improves DNA cloning reliability and efficiency, allowing successful cloning of genes and expression of recombinant proteins that had been impossible to clone or express with standard methods.

The Staby® technology allows producing proteins and DNA without the use of antibiotics. This is of special importance for large scale protein or DNA productions in the Biopharmaceutical Industry. Our patented stabilization technology dramatically improves the overall production yield and reproducibility. Our technology enables you to implement a completely “antibiotic-free“ production platform thus complying with the latest FDA and EMEA standards.

Through its Staby Operating System, an innovative set of bacterial strains and vectors integrating the Staby technology, Delphi Genetics offers a comprehensive range of molecular tools for DNA cloning and Protein expression.

Through its “Never Clone Alone“ Platform, Delphi Genetics is a dedicated service provider for custom services in Molecular cloning and Gene expression. We also offers research and development services for the biopharmaceutical industry.